Agilent Technologies Inc (A)vsCastle Biosciences Inc (CSTL)
A
Agilent Technologies Inc
$145.97
+3.28%
HEALTHCARE · Cap: $39.08B
CSTL
Castle Biosciences Inc
$32.03
+5.12%
HEALTHCARE · Cap: $928.40M
Smart Verdict
WallStSmart Research — data-driven comparison
Agilent Technologies Inc generates 1924% more annual revenue ($7.23B vs $357.28M). A leads profitability with a 19.6% profit margin vs -5.4%. A earns a higher WallStSmart Score of 71/100 (B).
A
Strong Buy71
out of 100
Grade: B
CSTL
Hold37
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-71.6%
Fair Value
$75.11
Current Price
$145.97
$70.86 premium
Margin of Safety
+59.2%
Fair Value
$79.18
Current Price
$32.03
$47.15 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 60.0% YoY
Strong operational efficiency at 23.7%
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Reasonable price relative to book value
Revenue surging 20.1% year-over-year
Areas to Watch
Moderate valuation
Grey zone — moderate risk
Weak financial health signals
Smaller company, higher risk/reward
Weak financial health signals
ROE of -2.8% — below average capital efficiency
Earnings declined 51.6%
Comparative Analysis Report
WallStSmart ResearchBull Case : A
The strongest argument for A centers on EPS Growth, Operating Margin. Profitability is solid with margins at 19.6% and operating margin at 23.7%. PEG of 1.23 suggests the stock is reasonably priced for its growth.
Bull Case : CSTL
The strongest argument for CSTL centers on Debt/Equity, Altman Z-Score, Price/Book. Revenue growth of 20.1% demonstrates continued momentum.
Bear Case : A
The primary concerns for A are P/E Ratio, Altman Z-Score, Piotroski F-Score.
Bear Case : CSTL
The primary concerns for CSTL are Market Cap, Piotroski F-Score, Return on Equity.
Key Dynamics to Monitor
A profiles as a mature stock while CSTL is a growth play — different risk/reward profiles.
A carries more volatility with a beta of 1.25 — expect wider price swings.
CSTL is growing revenue faster at 20.1% — sustainability is the question.
A generates stronger free cash flow (184M), providing more financial flexibility.
Bottom Line
A scores higher overall (71/100 vs 37/100), backed by strong 19.6% margins. CSTL offers better value entry with a 59.2% margin of safety. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Agilent Technologies Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Agilent Technologies, Inc. is an American analytical instrumentation development and manufacturing company that offers its products and services to markets worldwide. Its global headquarters is located in Santa Clara, California.
Castle Biosciences Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Castle Biosciences Inc. is a pioneering diagnostics firm that enhances patient care through advanced gene-expression profiling tests, particularly within the skin cancer sector, exemplified by its flagship product, DecisionDx®-Melanoma. This innovative test offers essential insights for risk stratification, enabling oncologists to make informed treatment decisions in managing melanoma. With a strong focus on precision medicine, coupled with an extensive research and development strategy, Castle Biosciences is poised for growth as it seeks to expand its offerings and meet critical clinical demands. By addressing the complexities inherent in oncology, the company not only aims to improve patient outcomes but also to generate substantial value for its investors.
Visit Website →Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?